| Document Date: 2014-01-29 12:46:55
Open Document File Size: 59,97 KBShare Result on Facebook
Company National Comprehensive Cancer Network Inc. / GlaxoSmithKline / / Country United States / / Event FDA Phase / / Facility National Library of Medicine / / IndustryTerm treatment of patients with unresectable or metastatic melanoma / in vitro diagnostic device / real-time polymerase chain reaction / diagnostic devices / / MedicalCondition metastatic BRAF-mutant cutaneous melanoma / tumor / melanoma / tumors / advanced solid tumors / Solid Tumors / J Cancer / metastatic melanoma / / Organization Food and Drug Administration / US Food and Drug Administration / / Person Silver Springs / / / Product Mekinist™ tablets / V600K / MEK2 / GDC-0973 / / URL http /
SocialTag |
PRIOR AUTHORIZATION POLICY Mekinist™ (trametinib tablets – GlaxoSmithKline) To Initiate a Coverage Review, Call[removed]OVERVIEW Mekinist is a kinase inhibitor indicated for the treatment of patients with unre